GlassScriptPhysician profile
Priya Maharaj
NPI 1891723672
$2,935.30
in general payments reported to CMS, 2019-2025
32 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $457 · 2021: $306 · 2022: $303 · 2023: $505 · 2024: $562 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $485.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $398.14 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Ibsa Pharma INC. | $373.54 | 2019-2024 | Tirosint, Licart, Tirosint |
| Abbvie INC. | $180.21 | 2019-2025 | |
| Galderma Laboratories, L.P. | $161.46 | 2019 | |
| Pfizer INC. | $155.06 | 2020-2025 | |
| Exact Sciences Corporation | $113.02 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.23 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $88.76 | 2022-2023 | |
| Glaxosmithkline, LLC. | $87.65 | 2019-2025 | Trelegy Ellipta |
| Corium, LLC | $75.22 | 2023 | Azstarys |
| Amneal Pharmaceuticals LLC | $73.77 | 2023-2025 | Unithroid |
| Amgen INC. | $66.28 | 2020-2025 | Repatha |
| Merck Sharp & Dohme LLC | $65.13 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.01 | 2020-2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $56.18 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $45.52 | 2024-2025 | Contrave |
| Novo Nordisk INC | $40.90 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $38.05 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $35.77 | 2019 | |
| Acella Pharmaceuticals, LLC | $30.42 | 2022-2023 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $28.73 | 2021 | |
| Abbott Laboratories | $27.99 | 2022-2023 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $25.49 | 2020 | |
| Janssen Pharmaceuticals, INC | $24.82 | 2024 | Spravato |
| Axsome Therapeutics, INC. | $18.98 | 2025 | Sunosi |
| Astellas Pharma US INC | $16.03 | 2025 | Veozah |
| Noven Therapeutics, LLC | $15.90 | 2024 | Xelstrym |
| Sanofi-Aventis U.S. LLC | $14.60 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.20 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.87 | 2024 | Nuzyra |
| Allergan, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Maharaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.